These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
118 related items for PubMed ID: 12515179
1. [Early diagnosis of nasopharyngeal carcinoma using recombinant antigens expressed in bacteria]. Wan Z, Pi G, Sun N. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Mar; 12(1):74-6. PubMed ID: 12515179 [Abstract] [Full Text] [Related]
2. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM. J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043 [Abstract] [Full Text] [Related]
3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX. Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282 [Abstract] [Full Text] [Related]
4. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, Benslimane A, Khyatti M. J Clin Microbiol; 2001 Sep 15; 39(9):3164-70. PubMed ID: 11526145 [Abstract] [Full Text] [Related]
10. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Chow KC, Ma J, Lin LS, Chi KH, Yen SH, Liu SM, Liu WT, Chen WK, Chang TH, Chen KY. Cancer Epidemiol Biomarkers Prev; 1997 May 15; 6(5):363-8. PubMed ID: 9149897 [Abstract] [Full Text] [Related]
11. [The purification and application of Epstein-Barr virus gp125]. Wang G, Pi G, Gu S. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun 15; 12(2):143-6. PubMed ID: 12515193 [Abstract] [Full Text] [Related]
12. Use of recombinant Epstein-Barr virus early antigen for detection of antibody in patients with nasopharyngeal carcinoma. Liu MT, Lin LS, Yu Y, Chung TT, Hsu CY, Chen JT, Jeng KC. Zhonghua Yi Xue Za Zhi (Taipei); 1996 Jan 15; 57(1):7-15. PubMed ID: 8820030 [Abstract] [Full Text] [Related]
13. Epstein-Barr virus seroepidemiology in China. Zeng Y, Pi GH, Deng H, Zhang JM, Wang PC, Wolf H, De Thé G. AIDS Res; 1986 Dec 15; 2 Suppl 1():S7-15. PubMed ID: 3030349 [Abstract] [Full Text] [Related]
14. Detection of IgA against Epstein-Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein. Shu CH, Tu TY, Lin LS, Ro LH, Lo MS, Huang CH, Chen KY, Liu WT. Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun 15; 62(6):350-5. PubMed ID: 10389292 [Abstract] [Full Text] [Related]
17. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma. Liu MY, Huang YT, Sheen TS, Chen JY, Tsai CH. J Med Virol; 2004 Aug 15; 73(4):574-82. PubMed ID: 15221902 [Abstract] [Full Text] [Related]
18. Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Deng H, Zeng Y, Lei Y, Zhao Z, Wang P, Li B, Pi Z, Tan B, Zheng Y, Pan W. Chin Med J (Engl); 1995 Apr 15; 108(4):300-3. PubMed ID: 7789220 [Abstract] [Full Text] [Related]